New Amsterdam Partners LLC NY grew its stake in Cambrex Co. (NYSE:CBM) by 124.9% during the third quarter, HoldingsChannel reports. The firm owned 132,969 shares of the biotechnology company’s stock after purchasing an additional 73,843 shares during the period. Cambrex makes up approximately 2.3% of New Amsterdam Partners LLC NY’s portfolio, making the stock its 7th largest position. New Amsterdam Partners LLC NY’s holdings in Cambrex were worth $9,095,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new position in shares of Cambrex in the second quarter valued at approximately $178,000. Telemus Capital LLC bought a new position in shares of Cambrex in the third quarter valued at approximately $243,000. Pitcairn Co. bought a new position in shares of Cambrex in the third quarter valued at approximately $253,000. Zebra Capital Management LLC bought a new position in shares of Cambrex in the second quarter valued at approximately $200,000. Finally, D.A. Davidson & CO. bought a new position in shares of Cambrex in the second quarter valued at approximately $216,000.
A number of analysts recently commented on CBM shares. Zacks Investment Research upgraded Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 price target on the stock in a report on Wednesday, August 8th. Jefferies Financial Group started coverage on Cambrex in a report on Tuesday, September 25th. They set a “buy” rating and a $75.50 price target on the stock. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $74.25.
In other Cambrex news, CEO Steven M. Klosk sold 55,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $66.30, for a total value of $3,646,500.00. Following the sale, the chief executive officer now directly owns 138,328 shares in the company, valued at $9,171,146.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Tom George Vadaketh sold 9,510 shares of the business’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $63.42, for a total value of $603,124.20. Following the completion of the sale, the chief financial officer now owns 9,510 shares in the company, valued at $603,124.20. The disclosure for this sale can be found here. Insiders have sold 84,510 shares of company stock worth $5,344,824 over the last quarter. 2.42% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “New Amsterdam Partners LLC NY Has $9.10 Million Stake in Cambrex Co. (CBM)” was posted by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.wkrb13.com/2018/11/07/new-amsterdam-partners-llc-ny-has-9-10-million-stake-in-cambrex-co-cbm.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
Further Reading: Why is the ex-dividend date different from the record date?
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.